Leucid Bio is pioneering advancements in CAR-T cell therapy through its proprietary Lateral CAR platform, which is designed to enhance the efficacy of T-cell therapies for treating refractory cancers. This innovative approach, developed from over 20 years of research led by Dr. John Maher, involves a novel CAR structure that mimics the natural lateral distribution of signaling domains found in immune receptors. This design allows CAR-T cells to achieve superior performance compared to previous generations, resulting in increased T-cell potency, improved long-term responses, and reduced toxicity. The lead asset, LEU011, targets NKG2D ligands and is currently in pre-clinical development, showing promise for treating various solid tumors and hematological malignancies.

In addition to the Lateral CAR platform, Leucid Bio has developed T4 Immunotherapy, a targeted autologous CAR T-cell product aimed at patients with otherwise untreatable head and neck cancer, which is currently in Phase I trials. The company has also created a patented technique for generating gd T-cells from healthy donors, known as T2, which are suitable for off-the-shelf therapies. Furthermore, Leucid Bio has established novel manufacturing platforms that streamline the production of CAR T-cells from a simple blood draw, enhancing scalability and reducing costs. This integrated approach aims to address the challenges faced in treating solid tumors, ultimately striving to improve patient outcomes in cancer therapy.

United Kingdom

Leucid is progressing novel CAR T therapies that produce a better and more durable response than previous CAR T generations, improving treatment outcomes and saving the lives of patients with refractory cancers.

Leucid Bio

Company Details